Lineage Cell Therapeutics, Inc.

$1.183
USD
Last updated on --.
24h volume2.42K
24h highest1.2100 USD
24h lowest1.1860 USD
24h Price movement-1.40%

LCTX recent prices

24 Hours
-1.40%-$0.0168
30 days
-17.81%-$0.26
60 days
-22.08%-$0.34
90 days
-35.14%-$0.65

Key data

Previous close1.2000 USD
Market cap331.57M USD
Volume2.42K
P/E ratio--
Dividend yield (TTM)0.00%
Dividend amount--
Next ex-dividend date--
Next payment date--
EPS diluted (TTM)-0.26000 USD
Net income (FY)-64.01M USD
Revenue (FY)14.78M USD
Last report dateMay 12, 2026

About Lineage Cell Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HeadquartersCARLSBAD
Employees (FY)77.00
Revenue per employee (FY)191.94K USD
Net income per employee (FY)-831.34K USD
Listed onXASE
Official website

LCTX conversion tables

LCTXLCTX
USDUSD
0.5 LCTX0.5916 USD
1 LCTX1.183 USD
5 LCTX5.916 USD
10 LCTX11.83 USD
USDUSD
LCTXLCTX
0.5 USD0.42258 LCTX
1 USD0.84517 LCTX
5 USD4.225 LCTX
10 USD8.451 LCTX

FAQ

LCTX is trading at $1.183, -1.40% over the last 24 hours. Track live moves on the price chart at the top of this page.
The LCTX stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. LCTX is currently trading at $1.183, -1.40% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on LCTX price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.
P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. LCTX's P/E ratio is currently -- — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from LCTX; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against LCTX's historical range and other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.
Lineage Cell Therapeutics, Inc.'s market cap is currently 331.57M USD. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.
24h volume2.42K
24h highest1.2100 USD
24h lowest1.1860 USD
24h Price movement-1.40%
LCTXLCTX
USDUSD
Start trade with LCTX Perpetual